← Back to Clinical Trials
Recruiting Phase 4 NCT04372277

Taltz in Combination With Enstilar for Psoriasis

Trial Parameters

Condition Psoriasis
Sponsor Psoriasis Treatment Center of Central New Jersey
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 25
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2020-04-28
Completion 2021-03-01
Interventions
Enstilar

Brief Summary

Enstilar in combination with Taltz for plaque psoriasis.

Eligibility Criteria

Inclusion Criteria: * Male or female adult ≥ 18 years of age; * Diagnosis of chronic plaque-type * Body Surface Area between 3%-8%. * Patient has been treated with Taltz for a minimum of 24 weeks * Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide. * Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination * Able and willing to give written informed consent prior to performance of any study-related procedures. Exclusion Criteria -˂3% or \>8% BSA * Patient not receiving Taltz, or receiving Taltz \<24 weeks * Any condition, which would p

Related Trials